Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flonoltinib maleate in intermediate- or high-risk myelofibrosis refractory/intolerant to JAK inhibitors (Phase IIb)
ChiCTR2600123044Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of flonoltinib in primary myelofibrosis (PMF) and myelofibrosis (MF), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Percentage of subjects with ≥35% reduction in spleen volume from baseline (primary). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
flonoltinib
03
Conditions
primary myelofibrosis (PMF)myelofibrosis (MF)
Beyond the preview
Go deeper on ChiCTR2600123044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123044.